APA (7th ed.) Citation

LK, N., PP, S., H, L., A, K., M, G., & M, S. (2026). Case Report: Switching secukinumab to bimekizumab in diffuse cutaneous systemic sclerosis after autologous hematopoietic stem cell transplantation: a case follow-up. Frontiers in immunology, 17, 1771650. https://doi.org/10.3389/fimmu.2026.1771650

Chicago Style (17th ed.) Citation

LK, Nagler, Strunz PP, Labinsky H, Kroiß A, Gernert M, and Schmalzing M. "Case Report: Switching Secukinumab to Bimekizumab in Diffuse Cutaneous Systemic Sclerosis After Autologous Hematopoietic Stem Cell Transplantation: A Case Follow-up." Frontiers in Immunology 17 (2026): 1771650. https://doi.org/10.3389/fimmu.2026.1771650.

MLA (9th ed.) Citation

LK, Nagler, et al. "Case Report: Switching Secukinumab to Bimekizumab in Diffuse Cutaneous Systemic Sclerosis After Autologous Hematopoietic Stem Cell Transplantation: A Case Follow-up." Frontiers in Immunology, vol. 17, 2026, p. 1771650, https://doi.org/10.3389/fimmu.2026.1771650.